NIFTY TIPS

Dishman Pharmaceuticals & Chemicals BSE NOTICES

Dishman Pharmaceuticals and Chemicals Ltd has informed BSE about commissioning of its World-class High Containment API facility for manufacture of a range of Oncology APIs and other related high potency products at its Bavla complex, near Ahmedabad. This facility has been set up primarily by the Technical Team of Dishman's Swiss Subsidiary namely Carbogen Amcis AG. with active support of local Dishman team. This facility is, to the best of Company's knowledge, the only one of its kind not only in India, but in the entire Asia and comparable with very few such facilities in the world. This is a significant milestone in the history of the Company and opens up huge opportunities for manufacture of high potency oncology APIs for manufacture of High value Oncology APIs and similar product on Contract Manufacturing Basis for the leading pharmaceuticals Companies in the World. This facility has been set up at approximate outlay of around USD 20 million.

Source: BSE
Courtesy moneycontrol.com

Also check

Dishman Pharmaceuticals & Chemicals NSE NOTICES

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Board of Directors of the Company has, in its meeting held on January 12, 2010, approved the proposal of issue of Non- Convertible Debentures (NCD) up to an amount of INR 750 million, for augmenting medium to long term resources of the Company, including regular capital expenditure.

Source: NSE
Courtesy moneycontrol.com

Also check

Dishman Pharmaceuticals & Chemicals BSE NOTICES

Dishman Pharmaceuticals and Chemicals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 12, 2010, has approved the proposal of issue of Non-Convertible Debentures (NCD) up to an amount of INR 750 million, for augmenting medium to long term resources of the Company, including regular capital expenditure.

Source: BSE
Courtesy moneycontrol.com

Also check